This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freeth, J. S. Articles by Clayton, P. E. Search for Related Content PubMed PubMed Citation Articles by Freeth, J. S. Articles by Clayton, P. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dietary Proteins Dwarfism

Activation of the Signal Transducers and Activators of Transcription Signaling Pathway by Growth Hormone (GH) in Skin Fibroblasts from Normal and GH Binding Protein-Positive Laron Syndrome Children

Endocrine Sciences Research Group (J.S.F., A.J.W., P.E.C.), Department of Medicine, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, United Kingdom; and Division of Endocrinology (C.M.S.), Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908

Address all correspondence and requests for reprints to: Dr. P. E. Clayton, Endocrine Sciences Research Group, Department of Medicine, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, United Kingdom. E-mail: peter.clayton{at}man.ac.uk

We have previously described two families (H and M) with GH binding protein-positive Laron Syndrome (LS), proposed to have one or more post GHR signaling defects. In the present study, we have examined whether the signal transducers and activators of transcription (STAT) pathway is activated by GH in skin fibroblast cultures established from these LS children, to determine the level(s) at which GH insensitivity has occurred.

On immunoblots, both normal and LS fibroblasts express JAK2 and STATs 1, 3, and 5. GH induced rapid tyrosine phosphorylation of a protein at approximately 93 kDa in normal fibroblasts, and Western blotting with STAT-specific antibodies revealed STAT5 activation (phosphorylation) by GH. To determine further the identity and the DNA binding characteristics of the STAT proteins that were activated by GH, EMSAs were performed using three DNA elements known to bind STAT proteins; m67, the high affinity c-sis-inducible element (SIE), the interferon response element (IRE), and the lactogenic hormone-responsive region (LHRR). GH failed to induce protein binding to the SIE or IRE in normal skin fibroblasts but did induce the formation of a specific complex with the LHRR. Induction by GH of this LHRR/protein complex, which could be supershifted partially by anti-STAT1 antisera and completely by anti-STAT5 antisera, was transient, maximal between 10 and 30 min and reduced by 60 min. GH also induced distinct LHRR/protein complexes in mouse 3T3-F442A fibroblasts and in human IM-9 lymphocytes, but supershift analysis revealed that these complexes contained STAT5 but not STAT1. Whereas no binding to the LHRR was observed in GH-treated H fibroblasts, GH induced binding to this element in M fibroblasts.

These results demonstrate that 1) the JAK-STAT pathway is activated by GH in normal fibroblasts and that STATs 1 and 5 have a role in GH-dependent signaling in these cells; 2) GH activation of DNA/STAT binding is cell type- and species-specific; and 3) GH failed to activate the STAT pathway in H fibroblasts but induced STAT signaling in M fibroblasts, indicating that the site of GH resistance in the latter is likely to be located within another GH signaling pathway. These fibroblast cultures therefore provide unique models with which to further our understanding of the mechanisms of human GH signaling.

This article has been cited by other articles:

				J. Xu, S. Ji, D. Y Venable, J. L Franklin, and J. L Messina Prolonged insulin treatment inhibits GH signaling via STAT3 and STAT1 J. Endocrinol., March 1, 2005; 184(3): 481 - 492. [Abstract] [Full Text] [PDF]

				R. G. Rosenfeld and V. Hwa Toward a Molecular Basis for Idiopathic Short Stature J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1066 - 1067. [Full Text] [PDF]

				S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF]

				E. M. Kofoed, V. Hwa, B. Little, K. A. Woods, C. K. Buckway, J. Tsubaki, K. L. Pratt, L. Bezrodnik, H. Jasper, A. Tepper, et al. Growth Hormone Insensitivity Associated with a STAT5b Mutation N. Engl. J. Med., September 18, 2003; 349(12): 1139 - 1147. [Full Text] [PDF]

				C. M. Silva, M. T. Kloth, A. J. Whatmore, J. S. Freeth, N. Anderson, K. K. Laughlin, T. Huynh, A. J. Woodall, and P. E. Clayton GH and Epidermal Growth Factor Signaling in Normal and Laron Syndrome Fibroblasts Endocrinology, July 1, 2002; 143(7): 2610 - 2617. [Abstract] [Full Text] [PDF]

				V. Beauloye, B. Willems, V. de Coninck, S. J. Frank, M. Edery, and J.-P. Thissen Impairment of Liver GH Receptor Signaling by Fasting Endocrinology, March 1, 2002; 143(3): 792 - 800. [Abstract] [Full Text] [PDF]

				M. Salerno, B. Balestrieri, E. Matrecano, A. Officioso, R. G. Rosenfeld, S. Di Maio, G. Fimiani, M. V. Ursini, and C. Pignata Abnormal GH Receptor Signaling in Children with Idiopathic Short Stature J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3882 - 3888. [Abstract] [Full Text] [PDF]

				R. Baetta, M. Soma, C. De-Fraja, C. Comparato, C. Teruzzi, L. Magrassi, and E. Cattaneo Upregulation and Activation of Stat6 Precede Vascular Smooth Muscle Cell Proliferation in Carotid Artery Injury Model Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 931 - 939. [Abstract] [Full Text] [PDF]

				K. Iida, Y. Takahashi, H. Kaji, N. Onodera, M. O. Takahashi, Y. Okimura, H. Abe, and K. Chihara The C422F Mutation of the Growth Hormone Receptor Gene Is Not Responsible for Short Stature J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4214 - 4219. [Abstract] [Full Text]

				J. Wojcik, M. A. Berg, N. Esposito, M. E. Geffner, N. Sakati, E. O. Reiter, S. Dower, U. Francke, M.-C. Postel-Vinay, and J. Finidori Four Contiguous Amino Acid Substitutions, Identified in Patients with Laron Syndrome, Differently Affect the Binding Affinity and Intracellular Trafficking of the Growth Hormone Receptor J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4481 - 4489. [Abstract] [Full Text]

				D. W. Love, A. J. Whatmore, P. E. Clayton, and C. M. Silva Growth Hormone Stimulation of the Mitogen-Activated Protein Kinase Pathway Is Cell Type Specific Endocrinology, April 1, 1998; 139(4): 1965 - 1971. [Abstract] [Full Text] [PDF]